

Medication Pipeline Report 2026 | Q1

TABLE OF CONTENTS

INTRODUCTION	3
SPECIALTY BRAND APPROVALS	4
NON-SPECIALTY BRAND APPROVALS	8
ADDITIONAL BRAND APPROVALS	11
PRODUCTS IN THE PIPELINE	15

GLOSSARY:

- PO Oral
- IV Intravenous
- SC Subcutaneous
- IM Intramuscular
- INH Inhaled
- INJ Injectable
- TD Transdermal
- ID Intradermal
- IVT Intravitreal
- TOP Topical
- OPHT Ophthalmic
- IN ... Intranasal
- IA Intra-arterial
- IT Intrathecal
- OT Otic
- CVC Catheter Lock Solution
- ICI Intracamera I implant

INTRODUCTION

Welcome to the Capital Rx Pipeline Report. This quarterly publication is developed by our Clinical Pharmacists and is prepared using a wide range of clinical resources. The Capital Rx Pipeline Report is designed to keep you up to date on the latest drug approvals and well-versed on what is to come in the FDA drug pipeline. Our pipeline report is one of the many ways we, at Capital Rx, demonstrate our commitment to providing clients and partners the tools and resources they desire.

WHO WE ARE

Capital Rx is a next generation pharmacy benefits manager, overseeing prescription benefit plans on behalf of employers, unions, and government entities. Determined to transform an outdated model, Capital Rx's mission is to change the way prescription benefits are priced and administered in the US, unlocking enduring social change. Through our platform approach, Capital Rx delivers data-driven insights and actionable strategies that reduce costs, while improving patient outcomes. Our commitment to innovation, technology and service is the reason why Capital Rx is among the fastest-growing PBMs in the country.



Privacy Statement:

This privacy policy describes the types of information we may collect from you or that you may provide when you visit the website cap-rx.com and our practices for collecting, using, maintaining, protecting, and disclosing that information. Capital Rx, Inc. (“we,” “our,” or “us”) is committed to ensuring that your privacy is protected. This policy applies to information we may collect through cap-rx.com, including any services offered on or through cap-rx.com such as the prescription benefit member web portal, and our mobile application accessible at the Google Play Store and iOS App Store under the name Capital Rx (collectively, our “Site”).

The drug pipeline is subject to change.
Information in this report is current as of:
03/16/2026

BONCRESA™ (DENOSUMAB-MOBZ) SC, AMNEAL, MABXIENCE

Approval Date	12/19/2025
Indication	Increasing bone mass, osteoporosis, and glucocorticoid-induced osteoporosis
Clinical Overview	Osteoporosis is caused by excessive reabsorption of bone which causes bones to weaken and become prone to fractures. It is the most common bone disease that affects more women than men. About 1 in every 3 women and 1 in every 5 men over the age of 50 develop osteoporosis. Risk factors for osteoporosis include age, female gender, previous fractures, menopause, family history, smoking, alcohol, poor nutrition, and vitamin D deficiency. Both prostate and breast cancer can lead to significant loss in bone mass. Breast cancer causes an increase in osteoclast activity while prostate cancer causes an increase in osteoblast activity. Though prostate cancer causes new bone to form, it is spongy instead of compact and leads to a decrease in bone strength and function.
Considerations	Biosimilar to Prolia® • Healthcare administered
Select Alt Therapies	Prolia® (denosumab) SC, Conexence® (denosumab-bnht) SC, Jubbonti® (denosumab-bbdz) SC, Stoboclo® (denosumab-bmwo) SC, Ospomyv™ (denosumab-dssb) SC

OZILTUS™ (DENOSUMAB-MOBZ) SC, AMNEAL, MABXIENCE

Approval Date	12/19/2025
Indication	Hypercalcemia of malignancy, bone metastases, and giant cell tumor of bone
Clinical Overview	Hypercalcemia of malignancy is mostly caused by too much parathyroid hormone related peptide from tumors, cancer attacking the bone releasing calcium, or multiple myeloma tumors in the bone. Typical symptoms include fatigue, constipation, decreased appetite, bone/muscle pain, and in more severe cases, irregular heartbeat, vomiting, pain with urination, and stomach pain. Bone metastases tumors usually come from other cancer tissues in the body like breast, lung, prostate (most common), or myeloma. Bone pain that is dull is a frequent symptom of bone metastases. Giant cell tumor of the bone is an aggressive tumor that is usually localized and occurs in about 1.6 per 100,000 people in the US per year. It typically occurs in the distal femur and proximal tibia.
Considerations	Biosimilar to Xygeva® • Healthcare administered
Select Alt Therapies	Xygeva® (denosumab) SC, Bomynta® (denosumab-bnht) SC, Osenvelt® (denosumab-bmwo) SC, Wyost® (denosumab-bbdz) SC, Xybrx® (denosumab-dssb) SC

AQVESME™ (MITAPIVAT) PO, AGIOS PHARMACEUTICALS

Approval Date	12/23/2025
Indication	Anemia in adults with alpha or beta thalassemia
Clinical Overview	Thalassemia is a genetic disorder that results in low hemoglobin, decreased red blood cell production, and anemia. The 2 main forms of thalassemia are alpha and beta that are caused by reduced/absent production of alpha-globulin or beta-globulin subunits, respectively. These forms can vary greatly in severity of anemia with severe anemia causing symptoms of weakness, shortness of breath, fatigue, dizziness, and headaches. Thalassemia can cause complications such as heart disease, liver disease, endocrine disease, hepatosplenomegaly, and skeletal manifestations.
Considerations	Annual WAC is \$425,094 • Black box warning for hepatocellular injury • Available only through a Risk Evaluation and Mitigation Strategy (REMS) program • First treatment to receive FDA approval for both types of thalassemia
Select Alt Therapies	For beta thalassemia it will compete with Reblozyl® (luspatercept-aamt) SC, Casgevy® (exagamglogene autotemcel) IV, Zynteglo™ (betibeglogene autotemcel) IV, and hematopoietic stem cell transplant (HSCT). Off-label hydroxyurea is the only therapy used for non-transfusion-dependent beta thalassemia and limited therapies exist for alpha thalassemia.

YARTEMLEA™ (NARSOPLIMAB-WUUG) IV, OMEROS

Approval Date	12/23/2025
Indication	Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in patients ≥2 years old
Clinical Overview	TA-TMA is a life-threatening complication of hematopoietic stem cell transplant that is caused by tiny blood clots forming in small blood vessels. It is classified as a group of syndromes that cause microangiopathic hemolytic anemia, thrombocytopenia, and organ injury. The most common organs damaged are the kidneys and brain. TA-TMA or high-risk TA-TMA affects about 20% of patients who undergo allogeneic hematopoietic stem cell transplant.
Considerations	1 st and only FDA approved therapy for this condition • WAC for one adult dose is \$36,805 • Healthcare administered • FDA granted Priority Review, Breakthrough Therapy, and Orphan Drug designations
Select Alt Therapies	No FDA approved medications on the market, but Soliris® (eculizumab) IV and Ultomiris® (ravulizumab-cwvz) IV have been used off-label in TA-TMA.

ZYCUBO® (COPPER HISTIDINATE) SC, SENTYNL THERAPEUTICS, ZYDUS

Approval Date	01/12/2026
Indication	Menke's disease in pediatrics
Clinical Overview	MD is a rare genetic X linked disorder that occurs in about 1 in 35,000 live male births. Most infants diagnosed with MD are male, though there are rare instances of MD occurring in females. This neurogenerative disorder leads to systemic copper deficiency and impairs the activity of multiple copper enzymes. Symptoms can include hypotonia, seizures, failure to thrive by 6-8 weeks, connective tissue abnormalities, Menke's kinky hair (short, coarse, twisted, and discolored hair), and progressive neurodegeneration. This disease has high mortality with most deaths occurring before the age of 3.
Considerations	1 st treatment FDA approved for Menke's disease • Administered by a healthcare provider or a caregiver, after receiving appropriate training • Annual WAC ranges from \$681,455-\$1,362,910 based on dosing
Select Alt Therapies	Only supportive care treatments have been used in the past, like seizure management, nutritional support, and management of recurrent infections. Copper supplements have also been used off label.

FILKRI™ (FILGRASTIM-LAHA) IV/SC, APOTEX, ACCORD, INTAS

Approval Date	01/15/2026
Indication	Treatment of neutropenia in patients with non-myeloid malignancies, in acute myeloid leukemia patients receiving chemotherapy and in cancer patients receiving bone marrow transplants
Clinical Overview	Most cancer patients develop neutropenia (low neutrophil count) due to chemotherapy, but it can also be caused by tumor malignancies, infiltrating the bone marrow, or by certain lymphoproliferative malignancies. Risk factors for developing neutropenia include old age, comorbidities, and history of cytotoxic chemotherapy. Types of chemotherapies can also determine risk for developing neutropenia as bone marrow transplantation usually leads to longer durations of neutropenia. Complications of neutropenia may include more severe infections, fevers, and neutropenic colitis (fever and abdominal pain are key symptoms).
Considerations	5 th filgrastim biosimilar approved in the US • Does not have interchangeable status with Neupogen®
Select Alt Therapies	Neupogen® (filgrastim) IV/SC, Nivestym® (filgrastim-aafi) IV/SC, Nypozi™ (filgrastim-txid) IV/SC, Releuko® (filgrastim-ayow) IV/SC, and Zarxio® (filgrastim-sndz) IV/SC

LOARGYS® (PEGZILARGINASE-NBLN) IV/SC, IMMEDICA PHARMA

Approval Date	02/23/2026
Indication	Hyperargininemia (ARG1-D) in adult and pediatric patients ≥ 2 years old with arginase 1 deficiency, in combination with dietary protein restrictions
Clinical Overview	Hyperargininemia is 1 of the 8 urea cycle disorder subtypes and is an ultra-rare autosomal recessive metabolic disorder that is inherited. Urea cycle disorders occur in about 1 in every 35,000 births and lead to toxic ammonia compounds not clearing from the body. This disorder is caused by complete or partial absence of the ARG1 enzyme in the liver and red blood cells. Deficiency in this enzyme leads to overaccumulation of plasma arginine and toxic metabolites. Symptoms can include seizures, spasticity, short stature, development delay, severe intellectual disability, and loss of ambulation.
Considerations	Granted FDA accelerated approval • Healthcare administered • Boxed warning for risk of hypersensitivity reactions • 1 st treatment to address persistently elevated levels of plasma arginine
Select Alt Therapies	Treatment is based on reducing ammonia and arginine concentrations in the blood. Dialysis and a combination of sodium phenylacetate and sodium benzoate are used to reduce ammonia/nitrogen levels. Seizures are usually treated with carbamazepine or phenobarbital.

YUWIWEL® (NAVEPEGITIDE) SC, ASCENDIS

Approval Date	02/27/2026
Indication	Achondroplasia in pediatric patients ≥ 2 years old
Clinical Overview	Achondroplasia (most common form of dwarfism) occurs in 1 in every 10,000-30,000 live births and is a genetic disorder caused by a gene mutation. The genetic mutation causes the fibroblast growth factor receptor 3 gene to be overly active. This leads to short stature and disproportionate growth. The average height of adults with achondroplasia is about 4 feet.
Considerations	Granted FDA accelerated approval and Priority Review designation
Select Alt Therapies	Voxzogo® (vosoritide) SC

NEREUS™ (TRADIPITANT) PO, VANDA PHARMACEUTICALS

Approval Date	12/30/2025
Indication	Motion sickness
Clinical Overview	Motion sickness affects about 25-30% of adults within the U.S, with about 65-78 million people affected. Motion sickness is caused by real or perceived motion and occurs from proprioceptive, vestibular, and visual senses being mixed. The release of substance P leads to nausea and vomiting. Symptoms may include nausea, vomiting, dizziness, increased salivation, sensation of bodily warmth, malaise, diaphoresis, and headache. Motion sickness usually peaks in those 7-12 years old and declines throughout adulthood.
Considerations	1 st motion sickness therapy to receive FDA approval in >40 years • WAC will be \$100-\$3,000 per single oral dose
Select Alt Therapies	Transderm Scōp® (scopolamine) and first-generation antihistamines (ex. dimenhydrinate and meclizine)

JOURNAVX® (SUZETRIGINE) PO, ENTASIS THERAPEUTICS

Approval Date	01/23/2026
Indication	Moderate to severe acute pain in adults
Clinical Overview	About 80 million people each year within the U.S. are prescribed a medicine for treatment of moderate to severe acute pain. Acute pain is classified as pain lasting less than 1 month. Onset is usually sudden and can be caused by injury, trauma or treatments like surgery.
Considerations	First in class, non-opioid pain medication • Has no addiction potential • FDA granted Breakthrough Therapy, Fast Track, and Priority Review designations • WAC for 14-day supply of treatment is about \$450
Select Alt Therapies	Typical treatment options for acute pain are nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen, Tylenol® (acetaminophen) PO, and opioids. Opioids (ex. morphine, oxycodone, etc.) are typically prescribed if patients cannot achieve relief with non-opioid medications first.

YUVEZZI® (BRIMONIDINE TARTRATE; CARBACHOL) OPHT, TENPOINT THERAPEUTICS, VISUS THERAPEUTICS

Approval Date	01/28/2026
Indication	Presbyopia
Clinical Overview	Presbyopia is a gradual decrease in near vision due to aging. It is caused by the crystalline lens of the eyes not being able to round and shape normally for near vision. It is the most common cause of visual impairment in the US with 110 million people being affected by it. 1.8 billion people around the world are affected by presbyopia. It typically starts at age 40 and can worsen over time until age 65.
Considerations	WAC around \$80 per month • 1 st dual agent product for this indication • Offers 10 hours of activity versus 6 hours that Vuity™ and Qlosi™ offer • Most payers do not cover due to corrective lenses availability
Select Alt Therapies	Vuity™ (pilocarpine hydrochloride) OPHT, Qlosi™ (pilocarpine hydrochloride) OPHT, Vizz (aceclidine) OPHT, or corrective lenses

ADQUEY™ (DIFAMILAST) TOP, OTSUKA, MEDIMETRIKS, AND ACROTECH BIOPHARMA

Approval Date	02/12/2026
Indication	Mild to moderate atopic dermatitis for adults and pediatric patients ≥2 years old
Clinical Overview	Atopic dermatitis is a chronic, relapsing skin condition that causes dry, itchy, and discolored patches of skin. It is one of the most common skin conditions as about 220 million people have it worldwide. This condition typically begins in childhood but can start at any age and is triggered by irritants, microbes, and allergens. Some patients outgrow the condition in adulthood while others have it chronically throughout life.
Considerations	Applied twice daily to skin compared to Zoryve® applied once daily • Higher selectivity for PDE4B subtype compared to other PDE4 inhibitors which targets inflammation
Select Alt Therapies	Eucrisa® (crisaborole) TOP and Zoryve® (roflumilast) TOP

BYSANTI™ (MILSAPERIDONE) PO, VANDA PHARMACEUTICALS

Approval Date	02/20/2026
Indication	Schizophrenia and acute manic or mixed episodes in those with bipolar I disorder
Clinical Overview	Schizophrenia is a severe chronic mental illness that occurs in about 1.2% of U.S. adults. The average age of onset is usually in the late teenage years or early twenties. Symptoms can include positive symptoms (hallucinations or delusions), negative symptoms (dull speaking, difficulty following through with tasks), and cognitive symptoms (struggling to remember things or organizing thoughts). Bipolar disorder is a chronic mood disorder that affects 5.7 million adult Americans. It causes intense shifts in mood, energy, and thinking patterns. Manic episodes are a key feature of bipolar 1 disorder and can include abnormally high mood, extreme changes in emotion or thoughts, and reckless behavior.
Considerations	Boxed warning for increased mortality in elderly patients with dementia-related psychosis
Select Alt Therapies	Atypical (2 nd generation) antipsychotics like Abilify® (aripiprazole) PO, Zyprexa® (olanzapine) PO, Seroquel® (quetiapine) PO

ADDITIONAL BRAND APPROVALS

BRAND NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	APPROVAL DATE
Mounjaro [®] tirzepatide	Eli Lilly	SC	Type II diabetes in pediatrics ≥10 years old	12/19/2025
Accrufer [®] ferric maltol	Shield Therapeutics	PO	Iron deficiency in pediatrics ≥10 years old	12/19/2025
Wegovy [®] semaglutide	Novo Nordisk	PO	Weight loss and to reduce cardiovascular mortality in patients with obesity	12/22/2025
Furoscix [®] furosemide	MannKind Corporation; scPharmaceuticals	SC	Edema associated with chronic heart failure or kidney disease in pediatrics (weight ≥43 kg)	12/22/2025
Cablivi [®] caplacizumab	Sanofi; Ablynx	IV, SC	Acquired thrombotic thrombocytopenic purpura (aTTP) for pediatrics ≥12 years old	12/23/2025
Cerezyme [®] imiglucerase	Sanofi; Genzyme	IV	Treatment of non-central nervous system manifestations of type I and type III gaucher disease (GD)	1/12/2026
Nexplanon [®] etonogestrel	Merck & Co; Organon	Implant	Extended its approved use for pregnancy prevention for up to 5 years	1/16/2026
Noxafil [®] posaconazole	Merck & Co	PO (tablet and power mix kit) and IV	Invasive aspergillosis	1/27/2026
Darzalex Faspro [®] daratumumab; hyaluronidase-fihj	Johnson & Johnson; Genmab; Halozyme Therapeutics	SC	Used in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant	1/27/2026
Keytruda [®] IV pembrolizumab	Merck & Co	IV	Platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1	2/10/2026

ADDITIONAL BRAND APPROVALS

BRAND NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	APPROVAL DATE
Keytruda Qlex™ berahyaluronidase alfa; pembrolizumab	Merck & Co	SC	Platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1	2/10/2026
Leqvio® inclisiran	Novartis	SC	Pediatric patients ≥12 years old with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH)	2/12/2026
Enzeevu™ aflibercept-abzv	Sandoz; Hexal	IVT	Macular edema following retinal vein occlusion, diabetic retinopathy, and diabetic macular edema	2/12/2026
Wakix® pitolisant hydrochloride	Bioproject; Harmony Biosciences	PO	Cataplexy in children ≥6 years old with narcolepsy	2/13/2026
Rybrevant Faspro™ amivantamab; hyaluronidase	Johnson & Johnson; Genmab; Halozyme Therapeutics	New once monthly dosing schedule: SC	EGFR-mutated advanced non-small cell lung cancer (NSCLC)	2/13/2026
Avopef™ etoposide	Avyxa Pharma	INJ	Adult patients with refractory testicular cancer and small cell lung cancer in combination with other chemotherapy	2/13/2026
Venclexta® venetoclax	Roche; Genentech; AbbVie	PO	First all-oral, fixed-duration regimen for treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in combination with Calquence®	2/19/2026
Calquence® acalabrutinib	AstraZeneca	PO	First all-oral, fixed-duration regimen for treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in combination with Venclexta®	2/19/2026

ADDITIONAL BRAND APPROVALS

BRAND NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	APPROVAL DATE
Elucirem™ gadopiclenol	Guerbet Group	IV	Pediatric patients ages 0-2 years old (including term neonates) for MRI scans	2/20/2026
Favlyxa™ flourouracil	Avyxa Pharma	IV	Adenocarcinoma of the colon, rectum, breast, stomach, and pancreas	2/20/2026
Dupixent® dupilumab	Sanofi; Genzyme; Regeneron	SC	Adults and pediatrics ≥6 years old with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery	2/23/2026
Braftovi® encorafenib	Pfizer; Array BioPharma	PO	Full approval for 1 st line treatment of BRAF V600E-mutant metastatic colorectal cancer in combination with cetuximab and chemotherapy (mFOLFOX6 or FOLFIRI)	2/24/2026
Desmoda™ desmopressin acetate	Eton Pharmaceuticals	New solution: PO	Central diabetic insipidus (arginine vasopressin deficiency)	2/25/2026
Hernexeos® zongertinib	Boehringer Ingelheim	PO	1 st line treatment for HER2-mutant, non-squamous non-small cell lung cancer (NSCLC)	2/26/2026
Prezcobix PED® cobicistat; darunavir ethanolate	Johnson & Johnson	New pediatric formulation: PO	Human immunodeficiency virus (HIV-1) in pediatrics ≥3 years old who weigh ≥15 kg	2/27/2026
Sogroya® somapacitan-beco	Novo Nordisk	SC	Idiopathic short stature (ISS), small for gestational age (SGA), and Noonan syndrome (NS) for pediatrics ≥2.5 years old	2/27/2026
Palynziq® pegvaliase-pqz	BioMarin	SC	Pediatrics 12-17 years old with phenylketonuria (PKU)	2/27/2026
Tecvayli® teclistamab	Janssen Biotech	SC	Full approval as monotherapy for adults with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy	3/5/2026

ADDITIONAL BRAND APPROVALS

BRAND NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	APPROVAL DATE
Pylarify Truvu™ piflufolastat F 18	Progenics Pharmaceuticals; Lantheus Medical Imaging; Aphelion	New formulation: IV	Diagnostic imaging in prostate cancer	3/6/2026
Sotyku™ deucravacitinib	Bristol-Myers Squibb	PO	Psoriatic arthritis	3/6/2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
reproxalap	AbbVie; Aldeyra	OPHT	Dry eye	03/16/2026
setmelanotide acetate	Rhythm Pharmaceuticals	SC	Hypothalamic obesity	03/20/2026
linerixibat	GSK	PO	Pruritus in primary biliary cholangitis	03/24/2026
marnetegrane autotemcel	Rocket Pharma	IV	Leukocyte adhesion deficiency (LAD)	03/28/2026
gallium-68 edotreotide	Lantheus Medical Imaging; Jubilant; Evergreen	IV	PET localization of neuroendocrine tumors	03/29/2026
ferric maltol	Shield Therapeutics	PO	Iron deficiency	1Q 2026
semaglutide (7.2 mg dose)	Novo Nordisk	SC	Obesity	1Q 2026
Doxorubicin	SkinJect Medicus	TD	Basal cell carcinoma	1Q 2026
insulin icodec	Novo Nordisk	SC	Type 2 diabetes glucose control	03/2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
nusinersen	Biogen Ionis Pharmaceuticals	IT	Spinal muscular atrophy	04/03/2026
tividenofusp alfa	Denali Therapeutics	IV	Mucopolysaccharidosis II (Hunter syndrome)	04/05/2026
orca-t (TBD)	Orca Bio	INJ	Conditioning for allogeneic hematopoietic stem cell transplantation	04/06/2026
nivolumab	Bristol-Myers Squibb; Onto Pharmaceutical	IV	Hodgkin's lymphoma	04/08/2026
vusolimogene oderparepvec	Replimune	INJ	Melanoma	04/10/2026
sparsentan	Ligand Pharmaceuticals; Retrophin Traverse Therapeutics	PO	Focal segmental glomerulosclerosis	04/13/2026
nimodipine	Acasti Grace Therapeutics	IV	Subarachnoid hemorrhage	04/23/2026
isatuximab	Sanofi; AbbVie; ImmunoGen	SC	Multiple myeloma	04/23/2026
dupilumab	Sanofi; Genzyme; Regeneron	SC	Chronic idiopathic urticaria (CIU)	04/27/2026
doravirine; islatravir	Merck & Co	PO	HIV-1 infection	04/28/2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
ustekinumab	Johnson & Johnson	SC; IV	Crohn's disease	04/2026
teplizumab	Sanofi; Provention Bio	IV	Delay of type I diabetes	04/29/2026
bupropion hydrochloride; dextromethorphan hydrobromide	Axsome	PO	Agitation in Alzheimer's disease	04/30/2026
efgartigimod alfa	Argenx	IV	Myasthenia gravis	05/10/2026
golimumab	Accord; Intas Bio-Thera Solutions	SC	Ulcerative colitis; ankylosing spondylitis; rheumatoid arthritis; psoriatic arthritis	05/16/2026
fam-trastuzumab deruxtecan	AstraZeneca; Daiichi Sankyo	IV	HER2-positive breast cancer	05/18/2026
lecanemab	Eisai; Biogen; BioArctic	SC	Alzheimer's disease	05/24/2026
cedazuridine; decitabine	Otsuka; Astex Pharmaceuticals	PO	Acute myeloid leukemia	05/25/2026
insulin recombinant human	MannKind Corporation	INH	Improve glycemic control in type 1 diabetes and type II diabetes	05/29/2026
lumateperone tosylate	Johnson & Johnson	PO	Long-term relapse prevention in schizophrenic patients	05/2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
guselkumab	Johnson & Johnson	IV; SC	Psoriatic arthritis	05/2026
dexmethylphenidate hydrochloride	Cingulate Therapeutics	PO	Attention deficit hyperactivity disorder (ADHD) in adults and children	05/31/2026
datopotamab deruxtecan	AstraZeneca; Daiichi Sankyo	IV	Breast cancer	06/02/2026
vepedgestrant	Pfizer; Arvinas	PO	Breast cancer	06/05/2026
ensitrelvir fumaric acid	Shionogi	PO	Prevention of Coronavirus disease 2019 (COVID-19) exposure	06/16/2026
pneumococcal 21-valent conjugate vaccine	Merck & Co; Ligand Pharmaceuticals	IM	Pneumococcal disease	06/18/2026
tebipenem pivoxil; hydrobromide	GSK; Meiki Seika; Spero Therapeutics	PO	Complicated urinary tract infection (UTI); pyelonephritis	06/18/2026
nilotinib	Xsray	PO	Chronic myeloid leukemia	06/18/2026
berahyaluronidase alfa; pembrolizumab	Merck & Co	SC	Kidney cancer	06/19/2026
pembrolizumab	Merck & Co	IV	Kidney cancer	06/19/2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
sodium oxybate	Tris Pharma	PO	Narcolepsy; idiopathic hypersomnia (IH)	06/20/2026
cytisinicline	Achieve Life Sciences	PO	Aid to smoking cessation	06/20/2026
oxylanthanum carbonate	Spectrum Therapeutics; Unicycive Therapeutics	PO	Hyperphosphatemia in chronic kidney disease	06/27/2026
pegadricase	Swedish Orphan Biovitrum; 3SBio Group; Selecta; Cartesian	IV	Gout	06/27/2026
roflumilast	Arcutis	TOP	Plaque psoriasis	06/29/2026
bulevirtide	Gilead; MYR Pharmaceuticals	SC	Hepatitis D	1H 2026
TBD (DB-OTO)	Regeneron; Decibel Therapeutics	INJ	Otoferlin-related hearing loss	1H 2026
brimonidine tartrate	Sun; Visiox Pharma; SPRAC; Ocuvox	OPHT	Open-angle glaucoma or ocular hypertension	1H 2026
anifrolumab	AstraZeneca; MedImmune	SC	Systemic lupus erythematosus	1H 2026
orforglipron	Eli Lilly; Chugai	PO	Obesity	1H 2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
camizestrant	AstraZeneca	PO	Hormone receptor positive breast cancer	1H 2026
teplizumab	Sanofi; Provention Bio	IV	Delay of type I diabetes	1H 2026
bupropion hydrochloride; dextromethorphan	Axsome	PO	Agitation in Alzheimer's disease	1H 2026
pivekimab sunirine	AbbVie; ImmunoGen	IV	Blastic plasmacytoid dendritic cell neoplasm	2Q 2026
ruxolitinib phosphate	Incyte	PO	Polycythemia vera; graft versus host disease; myelofibrosis	2Q 2026
baxdrostat	AstraZeneca; CinCor Pharma	PO	Hypertension	2Q 2026
cefepime; zidebactam	Wockhardt	IV	Complicated urinary tract infection (UTI); pyelonephritis	2Q 2026
budesonide; formoterol fumarate; glycopyrrolate	AstraZeneca; Pearl Therapeutics	INH	Asthma	2Q 2026
anifrolumab	AstraZeneca; MedImmune	SC	Systemic lupus erythematosus	2Q 2026
pegargiminase	Phoenix Polaris Group	IM	Mesothelioma	2Q 2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
durvalumab	AstraZeneca; MedImmune	IV	High-risk non-muscle invasive bladder cancer	2Q 2026
capivasertib	AstraZeneca; Astex Pharmaceuticals	PO	Prostate cancer	2Q 2026
benralizumab	AstraZeneca; MedImmune; Kyowa Kirin	SC	Hypereosinophilic syndrome	2Q 2026
trenibotulinumtoxinE	Allergan; AbbVie	IM	Glabella lines	2Q 2026
afilbercept	Bayer; Regeneron	IVT	Macular edema following retinal vein occlusion; diabetic macular edema, diabetic retinopathy; wet age-related macular degeneration	2Q 2026
gadoquatrane	Bayer	IV	For diagnostic MRI	2Q 2026
marstacimab	Pfizer	SC	Hemophilia A or B in patients with inhibitors	2Q 2026
sasanlimab	Pfizer	SC	Bladder cancer	2Q 2026
denosumab	Alkem Labs; Ascmed; Enzene	SC	Increasing bone mass; osteoporosis in men and postmenopausal women; glucocorticoid-induced osteoporosis	2Q 2026
denosumab	Alkem Labs; Ascmed; Enzene	TBD	Hypercalcemia of malignancy; bone metastases; giant cell tumor of bone	2Q 2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
sonrotoclax	BeiGene BeOne Medicines	PO	Mantle cell lymphoma	2Q 2026
ranibizumab	Lupin	IVT	Wet age-related macular degeneration	06/2026
trastuzumab	Tanvex	INJ	HER2-positive breast cancer	06/2026
veligrotug	Viridian Therapeutics	IV	Thyroid eye disease	06/30/2026
manganese chloride tetrahydrate	Ascelia	PO	For diagnostic MRI	07/03/2026
fam-trastuzumab deruxtecan	AstraZeneca; Daiichi Sankyo	IV	HER2-low breast cancer	07/07/2026
relacorilant	Corcept Therapeutics	PO	Ovarian cancer	07/11/2026
gedatolisib	Pfizer; Celcuity	IV	Hormone receptor positive, HER2(-) breast cancer	07/17/2026
camrelizumab	Jiangsu Hengrui Medicine	IV	Liver cancer	07/23/2026
rivoceranib mesylate	Jiangsu Hengrui Medicine; LSK BioPharma; HLB Pharma; Elevar Therapeutics	PO	Liver cancer	07/23/2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
centanafadine	Otsuka	PO	Attention deficit hyperactivity disorder	07/24/2026
furosemide	MannKind Corporation; scPharmaceuticals	SC	Chronic kidney disease; chronic heart failure	07/26/2026
ethinyl estradiol; norelgestromin	Mylan; Viatris	TD	Pregnancy prevention	07/30/2026
florquinitau	Lantheus Medical Imaging; Cerveau; LuMind IDSC; Engima Biomedical	IV	Alzheimer's disease	08/13/2026
iberdomide	Bristol-Myers Squibb; Celgene	PO	Multiple myeloma	08/17/2026
adrabetadex	Vtesse; Beren; Mandos Health	Intrathecal	Niemann-Pick disease type C	08/17/2026
molgramostim	PARI; Savara; Fujifilm	INH	Pulmonary alveolar proteinosis (PAP)	08/22/2026
deramiocel	Nippon Shinyaku; Capricor Therapeutics	IV	Cardiomyopathy associated with Duchenne muscular dystrophy	08/22/2026
pariglasgene breccaparvovec	Ultragenyx	IV	Von Gierke disease	08/23/2026
dasatinib	Xspray	PO	Acute lymphocytic leukemia; chronic myeloid leukemia	08/25/2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
lutetium lu 177 edotreotide	ITM	IV	Gastroenteropancreatic neuroendocrine tumors	08/28/2026
ropeginterferon alfa-2b	PharmaEssentia; AOP Orphan	SC	Thrombocytopenia	08/30/2026
garetoximab	Regeneron	IV	Fibrodysplasia ossificans progressiva (FOP)	08/2026
relabotulinumtoxinA	Galderma; Ipsen; Q-Med	IM	Lateral canthal lines; glabellar lines	08/2026
ustekinumab	Johnson & Johnson	SC; IV	Ulcerative colitis	08/2026
potassium bicarbonate; potassium citrate	Advicenne	PO	Renal tubular acidosis	09/03/2026
zidesamtinib	Nuvalent	PO	Non-small cell lung cancer (NSCLC)	09/18/2026
sotatercept	Bristol-Myers Squibb; Merck & Co; Celgene; Acceleron	SC	Pulmonary arterial hypertension	09/21/2026
aminolevulinic acid; hydrochloride	Biofrontera	TOP	Basal cell carcinoma	09/28/2026
breprocitinib	Pfizer; Roivant; Privant Therapeutics	PO; TOP	Dermatomyositis	3Q 2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
tiratricol	PledPharma; Egetis Therapeutics; Rare Thyroid Therapeutics	PO	MCT8 deficiency (Allan Herndon Dudley syndrome)	3Q 2026
lirafugratinib	Elevar Therapeutics; Relay Therapeutics	PO	Biliary tract cancer	3Q 2026
oveporexton	Takeda	PO	Narcolepsy	3Q 2026
atezolizumab	Roche; Genentech	IV	Bladder cancer	3Q 2026
beclomethasone dipropionate; formoterol fumarate dihydrate	Chiesi	INH	Asthma	3Q 2026
apixaban (oral dissolving film)	TAHO	PO	In patients with nonvalvular atrial fibrillation reduce risk of systemic embolism and stroke	3Q 2026
icotrokinra	Johnson & Johnson	PO	Plaque psoriasis	3Q 2026
denecimig	Novo Nordisk; Genmab	SC	Hemophilia A	3Q 2026
tavapadon	Pfizer; AbbVie; Cerevel Therapeutics	PO	Parkinson's disease	3Q 2026
rusfertide	Takeda; Protagonist Therapeutics	SC	Polycythemia vera	3Q 2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
condoliase	Ferring Pharmaceuticals; Seikagaku	INJ	Lumbar disc herniation (LDH)	09/2026
TBD (Pixclara)	Telix	IV	For diagnostic imaging in glioma	09/2026
lenvatinib mesylate	Eisai; Merck & Co	PO	Kidney cancer	10/04/2026
belzutifan	Merck & Co; Pelton Therapeutics	PO	Kidney cancer	10/04/2026
phentolamine mesylate	Ocuphire Pharma; Viatris; Opus Genetics	OPHT	Presbyopia	10/17/2026
doruxapapogene ralaplasamid	Inovio	IM	Recurrent respiratory papillomatosis (RRP)	10/30/2026
aflibercept	Sam Chun Dan Pharm; Fresenius Kabi	IVT	Wet age-related macular degeneration; diabetic retinopathy, diabetic macular edema; macular edema following retinal vein occlusion	10/2026
ivonescimab	Summit Therapeutics; Akeso Biopharma	IV	Non-small cell lung cancer	11/14/2026
dexmedetomidine hydrochloride	BioXcel Therapeutics	PO	Acute agitation in bipolar patients and schizophrenic patients	11/2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
zanzalintinib	Exelixis	PO	Colorectal cancer	12/03/2026
imsidolimab	Vanda Pharmaceuticals; AnaptysBio	IV; SC	Pustular psoriasis	12/12/2026
giredestrant	Roche; Genentech	PO	Hormone receptor positive breast cancer	12/18/2026
tirabrutinib hydrochloride	Gilead; Ono Pharmaceutical	PO	Primary central nervous system lymphoma	12/18/2026
imlifidase	Hansa Biopharma	IV	Desensitization therapy in kidney transplant recipients	12/19/2026
lorundrostat	Mineralys Therapeutics	PO	Hypertension	12/22/2026
anitocabtagene autoleucel	Gilead; Kite Pharma; Arcellx	IV	Multiple myeloma	12/23/2026
bezuclastinib	Unum Therapeutics; Cogent Biosciences	PO	Systemic mastocytosis (SM)	12/30/2026
somapacitan	Novo Nordisk	SC	Short stature associated with Turner syndrome	2H 2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
gefurulimab	AstraZeneca; Alexion	SC	Myasthenia gravis	2H 2026
sacituzumab govitecan	Gilead; Immunomedics	IV	Breast cancer	2H 2026
meloxicam	Viartis	PO	Post-operative pain	2H 2026
relutrigine	Praxis Precision Medicines	PO	Developmental and epileptic encephalopathy (DEE)	2H 2026
remibrutinib	Novartis	PO	Chronic inducible urticaria (CIndU)	2H 2026
secukinumab	Novartis	SC	Polymyalgia rheumatica	2H 2026
tirzepatide	Eli Lilly	SC	Reduce cardiovascular mortality in patients with type II diabetes	2H 2026
nipocalimab	Momenta; Johnson & Johnson	IV	Warm antibody autoimmune hemolytic anemia	2H 2026
enfortumab vedotin	Pfizer; Astellas; Seattle Genetics; Seagen	IV	Bladder cancer	2H 2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
lutetium lu 177 vipivotide; tetraxetan	Novartis; Endocyte	IV	Prostate cancer	2H 2026
pimicotinib hydrochloride	EMD Serono; Abbisko Therapeutics	PO	Tenosynovial giant cell tumor (TGCT)	2H 2026
insulin efsitora alfa	Eli Lilly	SC	Improve glycemic control in type 2 diabetes	2H 2026
bictegravir; lenacapavir	Gilead	PO	HIV-1 infection	2H 2026
tildrakizumab	Sun; Merck & Co	SC	Psoriatic arthritis	2H 2026
omalizumab	Amneal; Kashiv BioSciences	SC	Chronic idiopathic urticaria (CIU)	4Q 2026
bevacizumab	Henlius	IV	Glioblastoma multiforme; colorectal cancer; cervical cancer	4Q 2026
zipalertinib	Taiho; Cullinan Pearl	PO	Non-small cell lung cancer	4Q 2026
aficamten	Cytokinetics	PO	Hypertrophic cardiomyopathy	4Q 2026

PRODUCTS IN THE PIPELINE

PIPELINE NAME (generic name)	COMPANY	ROUTE OF ADMINISTRATION	INDICATION(S)	PENDING FDA APPROVAL DATE
cabozantinib	Lotus Pharmaceutical	PO	Medullary thyroid cancer; kidney cancer; liver cancer; differentiated thyroid cancer	4Q 2026
olanzapine	Teva; Royalty Pharma; MedinCell	SC	Schizophrenia	4Q 2026
pirtobrutinib	Eli Lilly; Loxo Oncology	PO	Chronic lymphocytic leukemia	4Q 2026
cagrilintide; semaglutide	Novo Nordisk	SC	Obesity	4Q 2026
abatacept	Dr. Reddy's Laboratories	IV	Psoriatic arthritis; rheumatoid arthritis; juvenile idiopathic arthritis	12/2026
nogapendekin alfa inbakicept	NantiWorks; Altor BioScience; ImmunityBio	SC; Intravesical	Bladder cancer	12/2026